- Home
- SLN vs CAST Comparison
SLN vs CAST Comparison
Compare SLN & CAST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLN | CAST |
|---|---|---|
| Founded | 1994 | 2011 |
| Country | United Kingdom | United States |
| Employees | 116 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.2M | 194.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SLN | CAST |
|---|---|---|
| Price | $7.10 | $2.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $42.60 | $6.00 |
| AVG Volume (30 Days) | 426.8K | ★ 725.2K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.54 | $1.63 |
| 52 Week High | $8.40 | $4.90 |
Technical Indicators
Market Signals| Indicator | SLN | CAST |
|---|---|---|
| Relative Strength Index (RSI) | 54.38 | 39.66 |
| Support Level | $5.76 | $1.63 |
| Resistance Level | $7.53 | $4.83 |
| Average True Range (ATR) | 0.58 | 0.53 |
| MACD | 0.03 | -0.18 |
| Stochastic Oscillator | 60.25 | 21.46 |
Price Performance
Historical ComparisonAbout SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.